Pfizer Successfully Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc.
- Details
- Category: Pfizer
![Pfizer Inc Pfizer Inc](http://www.worldpharmanews.com/images/stories/logo/pfizer_b.gif)
Rasilez® reduces left ventricular hypertrophy, a powerful predictor of heart disease
- Details
- Category: Novartis
![Novartis AG Novartis AG](http://www.worldpharmanews.com/images/stories/logo/novartis_b.gif)
Bayer appeals invalidity ruling on its Yasmin® Patent
- Details
- Category: Bayer
![Bayer Group Bayer Group](http://www.worldpharmanews.com/images/stories/logo/bayer.gif)
Crestor Outcomes Study JUPITER Closes Early Due To Unequivocal Evidence Of Benefit
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](http://www.worldpharmanews.com/images/stories/logo/astrazeneca_b.gif)
Novel oral anticoagulant Pradaxa® (dabigatran etexilate) approved by the European Commission
- Details
- Category: Boehringer Ingelheim
![Boehringer Ingelheim Boehringer Ingelheim](http://www.worldpharmanews.com/images/stories/logo/boehringeringelheim.gif)
Levitra® - Therapy suitable for men with High Cholesterol
- Details
- Category: Bayer
![Bayer AG Bayer AG](http://www.worldpharmanews.com/images/stories/logo/bayer.gif)
Aurobindo Pharma expands in Europe
- Details
- Category: Business
Aurobindo Pharma announced that it has recently concluded a strategic deal, for acquisition of Intellectual Property & Marketing Authorizations, with TAD Italy, a generic company registered in Italy. This acquisition will give Aurobindo an access to more than 70 ready to market products which will fast track Aurobindo's entry into the Italian generic market.
More Pharma News ...
- GSK charitable support valued at £282 million in 2007
- Federal Court of Appeal in Canada Upholds Lipitor Enantiomer Patent
- Zevalin® Receives Positive CHMP Opinion in Europe for First-Line Consolidation Treatment
- Genzyme Withdraws Bioenvision's European Filing of Evoltra® in Elderly AML Patients
- GSK statement on MHRA investigation
- First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Trial Date Set For SEROQUEL® Patent Litigation